嵌合抗原受体修饰的T细胞治疗：发展的25年

icartab

Chimeric antigen receptor T cell therapy: 25years in the making.

Abstract

Chimeric antigen receptor (CAR) T cell therapy of cancer is generating enormous enthusiasm. Twenty-five years after the concept was first proposed, major advances in molecular biology, virology, and good manufacturing practices (GMP)-grade cell production have transformed antibody-T cell chimeras from a scientific curiosity to a fact of life for academic cellular immunotherapy researchers and, increasingly, for patients.In this review, we explain the preclinical concept, outline how it has been translated to the clinic, and draw lessons from the first years of CAR T cell therapy for the practicing clinician.

嵌合抗原受体修饰的T细胞治疗：发展的25年

摘要：

人们对利用嵌合抗原受体修饰的T细胞治疗癌症具有极大的热情。在这个概念第一次被提出后的25年之后，随着分子生物学、病毒学和GMP细胞制备的大力发展，已经使得细胞免疫治疗者以及越来越多的患者，利用T细胞治疗疾病的梦想走入现实。在这篇综述中，我们解释了临床前的一些概念，概述了CAR-T如何进入到临床，并借鉴第一年的CAR-T细胞治疗的临床实践。

出自爱康得生物技术